Business
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
BOSTON, May 01, 2025--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/910f7d1e60ade2abb3aabe09da32e8f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TWwlmaELmr8Yw08btYlODg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/910f7d1e60ade2abb3aabe09da32e8f8","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8Ez0CUJmuSGZu3FI.6JVCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/910f7d1e60ade2abb3aabe09da32e8f8","width":1200,"height":385}},"lazy":false},{"type":"text","content":"Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF)","length":193,"tagName":"p","attribs":{}},{"type":"text","content":"Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 01, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will deliver a late-breaking oral presentation at the upcoming American Thoracic Society (ATS) International Conference, taking place in San Francisco, California, from May 16-21, 2025.","length":466,"tagName":"p","attribs":{}},{"type":"text","content":"The presentation will highlight data from the recently completed Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), which demonstrated unprecedented efficacy outcomes in patients living with idiopathic pulmonary fibrosis (IPF), including the potential to stabilize lung function decline at 26 weeks while maintaining safety and tolerability.","length":346,"tagName":"p"},{"type":"text","content":""The Phase 2b ELEVATE IPF trial results represent a major advancement for the treatment of IPF," said Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer of PureTech. "Deupirfenidone demonstrated the potential to stabilize lung function decline ov...